Letters to the Editor

Breaking barriers in rare disease research: a pilot trial of thromboprophylaxis with apixaban versus aspirin in JAK2-Positive myeloproliferative neoplasms

Department of Medicine, The Ottawa Hospital, University of Ottawa, and The Ottawa Hospital Research Institute, Ottawa
Cumming School of Medicine, University of Calgary, Calgary
Service d’hémato-oncologie, Département de médecine, Centre hospitalier universitaire de Sherbrooke, Sherbrooke
Service d'Hématologie et d'Hémostase Clinique, Institut De Cancéro-Hématologie, INSERM, UMR1304, GETBO, Centre hospitalier universitaire de Brest, Brest France; France intergroupe des néoplasies myéloprolifératives (FIM), Paris
Department of Medicine, The Ottawa Hospital, University of Ottawa, and The Ottawa Hospital Research Institute, Ottawa
Department of Medicine, The Ottawa Hospital, University of Ottawa, and The Ottawa Hospital Research Institute, Ottawa
Department of Medicine, The Ottawa Hospital, University of Ottawa, and The Ottawa Hospital Research Institute, Ottawa
Department of Medicine, The Ottawa Hospital, University of Ottawa, and The Ottawa Hospital Research Institute, Ottawa
Haematologica Early view May 7, 2026 https://doi.org/10.3324/haematol.2026.301040